Literature DB >> 20109604

Amyloid heart disease.

Rodney H Falk1, Simon W Dubrey.   

Abstract

The systemic amyloidoses are an uncommon group of disorders characterized by the extracellular deposition of amyloid in one or more organs. Cardiac deposition, leading to an infiltrative/restrictive cardiomyopathy, is a common feature of amyloidosis. It may be the presenting feature of the disease or may be discovered while investigating a patient presenting with non-cardiac amyloidosis. In this article we review the features of cardiac amyloidosis and its varied manifestations. The need for a high index of suspicion and the critical importance of precise biochemical typing of the amyloid deposits is stressed in light of recent advances in therapy which can, when appropriately used, significantly improve prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20109604     DOI: 10.1016/j.pcad.2009.11.007

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  57 in total

Review 1.  The role of magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Edward T D Hoey; Mohamed Elassaly; Arul Ganeshan; Richard W Watkin; Helen Simpson
Journal:  Quant Imaging Med Surg       Date:  2014-10

2.  A rare cause of cardiac decompensation in a patient with left ventricular hypertrophy.

Authors:  Norman Mangner; Matthias Gutberlet; Karin Klingel; Reinhard Kandolf; Gerhard Schuler; Axel Linke
Journal:  Clin Res Cardiol       Date:  2012-05-30       Impact factor: 5.460

3.  Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats.

Authors:  Sanda Despa; Kenneth B Margulies; Le Chen; Anne A Knowlton; Peter J Havel; Heinrich Taegtmeyer; Donald M Bers; Florin Despa
Journal:  Circ Res       Date:  2012-01-24       Impact factor: 17.367

Review 4.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

5.  Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software.

Authors:  Tanja Kero; Lars Lindsjö; Jens Sörensen; Mark Lubberink
Journal:  J Nucl Cardiol       Date:  2015-07-15       Impact factor: 5.952

6.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

7.  Pursuing an underdiagnosed disease: a simple imaging test for increasing suspicion of cardiac amyloidosis.

Authors:  Rodney H Falk; Sharmila Dorbala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03       Impact factor: 9.236

8.  Novel Antibody for the Treatment of Transthyretin Amyloidosis.

Authors:  Akihiko Hosoi; Yu Su; Masaharu Torikai; Hirofumi Jono; Daisuke Ishikawa; Kenji Soejima; Hirofumi Higuchi; Jianying Guo; Mitsuharu Ueda; Genki Suenaga; Hiroaki Motokawa; Tokunori Ikeda; Satoru Senju; Toshihiro Nakashima; Yukio Ando
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

9.  The amyloidoses: clinical features, diagnosis and treatment.

Authors:  Kelty R Baker; Lawrence Rice
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

Review 10.  Novel drugs targeting transthyretin amyloidosis.

Authors:  Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.